Takeda Pharmaceutical Company Limited has granted Teva Pharmaceutical Industries Ltd. a license to market a generic version of ACTOS® in the U.S. beginning on August 17, 2012, and a generic version of ACTOplus met® beginning December 14, 2012. The license was granted following an agreement to settle patent litigation related to Teva’s generic versions of Takeda’s ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) in the United States.
Source: www.tevapharm.com
